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Summary
Chronic obstructive pulmonary disease (COPD) is a potentially severe chronic progressive
respiratory condition requiring long-term treatment and frequently involving episodic
hospitalisations to manage exacerbations. The objective of this analysis was to document
diagnosis, evaluation, treatment and management of COPD-related respiratory symptoms
in 1,392 subjects fulﬁlling an epidemiological deﬁnition of COPD identiﬁed in a general
population sample of 62,086 individuals aged40 years in ten countries in the Middle East and
North Africa region (Algeria, Egypt, Jordan, Lebanon, Morocco, Saudi Arabia, Syria, Tunisia,
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Turkey and United Arab Emirates), together with Pakistan. 442 subjects (31.8%) claimed
to have received a diagnosis of COPD from a physician and 287 (20.6%) had undergone
spirometry in the previous year. Use of speciﬁc treatments for respiratory symptoms was
reported by 218 subjects (15.7%). Use of inhaled long-acting bronchodilators together with
corticosteroids (53 subjects; 3.8%) and use of oxygen therapy (31 subjects; 2.3%) was very
low. 852 subjects (61.2%) had consulted a physician about their respiratory condition at least
once in the previous year, with a mean number of consultations of 3.4±3.6. Moreover,
284 subjects (20.4%) had been hospitalised overnight for their COPD, with a mean of
2.3±3.7 hospitalisations per year. Use of all healthcare resources was signiﬁcantly higher
(p < 0.001) in subjects with CAT scores 10 than in those with scores <10, and greater in
those with exacerbations than in those without. In conclusion, COPD in the region is under-
diagnosed, inadequately evaluated and inadequately treated. Nonetheless, COPD symptoms
are responsible for considerable healthcare consumption, with high levels of physician
consultation and hospitalisation.
© 2012 Elsevier Ltd. All rights reserved.
Introduction
COPD is considered to be both preventable and treatable1,2
but remains a major cause of chronic morbidity and
mortality worldwide.1 4 The impact of COPD on health
and quality of life, particularly in its severe stages (GOLD
2009 stages 3 and 4,1 or GOLD 2011 groups C and D5), is
profound.6,7 Dyspnoea signiﬁcantly restricts daily activities
and may severely affect quality of life, interfering with
everyday tasks such as dressing, washing, talking and
sleeping.6 Exacerbations of the disease may result in
medical emergency visits, hospitalisations and absenteeism
from work, which can have a signiﬁcant emotional impact on
COPD sufferers including social isolation and depression.6
Even stage I COPD, which may be asymptomatic or cause
only mild symptoms, can have a subtle effect on routine
daily activities and health-related quality of life.8 Stage I
subjects may experience exacerbations which may be
particularly debilitating and may have a signiﬁcant impact
on productivity at work and utilisation of health resources.8
The impact and evolution of stage I COPD can be
positively altered if management of disease symptoms,
activity limitations and exacerbations is started as early
as possible.8 However, even subjects with severe COPD
can experience modest improvements in lung function if
appropriate treatment is initiated.9
The ﬁrst clinical guidelines on the management of COPD
were published in 1997 and led to signiﬁcant improvements
in the recognition of COPD and its treatment.10 Since then a
number of new updated guidelines and an increasing range
of treatment options including several bronchodilator drugs,
respiratory rehabilitation and non-invasive ventilation in
respiratory failure have become available.1,5,9 13 It is
not known, however, how COPD management across the
world complies with current guidelines, since this will be
inﬂuenced by local access to healthcare and the availability
of effective medications.
In 2002, Rennard et al. published the results of the
Confronting COPD international surveys, aimed at assessing
the impact of COPD in North America and Europe and
including an assessment of health resource utilisation
and disease management.7 The results showed that COPD
subjects were generally poorly managed with available
treatments and highlighted the need for better education
of physicians on the nature of the disease and the
different treatment options available.7,14 Health resource
consumption and disease management are also addressed
in the Confronting COPD in America Executive Summary.6
Few data are available, however, on the management of
COPD in low- to middle-income countries, despite the fact
that tobacco consumption in these countries continues to
rise at an alarming rate.15 Furthermore, many smokers in
these countries also smoke tobacco using waterpipes and
these have been shown to signiﬁcantly16 increase the risk of
respiratory diseases, including COPD.16 19
We have recently performed a large epidemiological
survey of subjects presenting COPD-related symptoms in
the general populations of ten countries in the Middle East
and North Africa (MENA) region (Algeria, Egypt, Jordan,
Lebanon, Morocco, Saudi Arabia, Syria, Tunisia, Turkey and
UAE), together with Pakistan, using a standardised method-
ology, the BREATHE study.20 The study collected information
on risk factors, disease history, clinical symptoms, impact
on daily life, disease management and healthcare resource
consumption. This article describes the data collected on
diagnosis of COPD, treatments used and on how the disease
was managed.
Methods
This was a cross-sectional epidemiological survey of COPD
conducted in ten countries in the MENA region (Algeria,
Egypt, Jordan, Lebanon, Morocco, Saudi Arabia, Syria,
Tunisia, Turkey and UAE), together with Pakistan, between
June 2010 and December 2011. A detailed description
of the methodology used in the study can be found in
another article in this supplement.20 The present article
presents the data obtained on disease management across
the region.
Study sample
A general population sample of 10,000 subjects in each
country or zone was generated from random telephone
numbers. All subjects (males or females) aged 40 years
who agreed to participate in the study were eligible and
were proposed a structured telephone interview. Subjects
not domiciled in the country or zone in question, or those of
foreign origin resident in the country for <6 months at the
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time of the study were excluded from the study, as were
subjects with comorbid mental illness.
Data collection
When initial telephone contact with each subject was
established, the interviewer explained the goal of the study
and the next steps. Subjects who agreed to participate in
the study completed a ﬁrst screening questionnaire which
collected data on demographics, respiratory symptoms and
smoking habits.17,19,20
Subjects were considered to have symptomatic COPD
if they fulﬁlled the two criteria for the epidemiological
deﬁnition of COPD used in this study and outlined in
the methodology paper.20 The ﬁrst criterion was EITHER
a diagnosis of COPD, emphysema or chronic bronchitis
OR the presence of coughing with phlegm or sputum
(productive cough), breathlessness or symptoms consistent
with chronic bronchitis. The second criterion was a lifetime
smoking exposure of 10 pack·years. Subjects in the
COPD population were considered as positively screened
and were invited to undergo a second more detailed
telephone questionnaire on the disease (detailed COPD
subject questionnaire). This second questionnaire consisted
of 77 questions collecting information on risk factors,
comorbidities, disease history, clinical symptoms, impact on
daily life and disease management.
Subjects who were identiﬁed with COPD were also
asked to complete a COPD Assessment Test (CAT),21,22
which consists of eight items assessing health status
impairment in COPD. The ﬁnal score for this test ranges
from 0 to 40. The results of this test were used to classify
subjects into four groups depending on their symptoms and
risk of exacerbations, according to the recommendations
of the 2011 GOLD report5 (Fig. 1). Since the number
of exacerbations was not documented in the BREATHE
study, the GOLD classiﬁcation was adapted according to
exacerbation history (yes or no). An exacerbation was taken
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Figure 1. Classiﬁcation of COPD subjects in this study according
to their CAT score and exacerbation history (adapted from
the 2011 GOLD report5). Group A: low risk, less symptoms:
no exacerbations and CAT score <10; Group B: low risk, more
symptoms: no exacerbations and CAT score 10; Group C:
high risk, less symptoms: 1 exacerbation and CAT score <10;
Group D: high risk, more symptoms: 1 exacerbation, and CAT
score 10.
to have occurred in the previous six months if the subject
fulﬁlled any of the following criteria:
• Criterion 1: In the last 6 months, have you been told
by your physician that you have had worsening of your
“Respiratory Condition”? YES
• Criterion 2: In the last 6 months, have you been told by
your physician that you have had acute bronchitis? YES
• Criterion 3: In the last 6 months, what aspects of your
“Respiratory Condition” have worsened? (cough during the
daytime, cough during the night, phlegm, breathlessness
or shortness of breath and fatigue, ability to perform
regular activities) At least two symptoms cited
Statistical analysis
Data presentation is principally descriptive, with continuous
variables being presented as mean values ±SEM and
categorical variables as frequency counts (%). Missing data
were not replaced and the relatively few subjects for whom
data were missing were excluded from the calculation of
frequency rates. Variables were compared between the four
GOLD groups using the c2 test for categorical variables and
one-way analysis of variance for continuous variables.
Results
Study sample
A total of 62,086 subjects completed the screening
questionnaire. Of this population, 8,850 subjects reported
at least one COPD-related symptom, namely productive
cough or breathlessness. A total of 2,187 subjects fulﬁlled
the epidemiological deﬁnition of COPD,20 of whom 1,392
(63.6%) completed the detailed COPD subject question-
naire (from 37.0% in Pakistan to 89.5% in Morocco) and
constituted the study population. No relevant differences
in terms of age, gender and COPD symptoms (productive
cough, breathlessness or symptoms consistent with chronic
bronchitis) were found when comparing the COPD popu-
lation who completed the detailed questionnaire with all
2,187 subjects who fulﬁlled the epidemiological deﬁnition
of COPD. The demographic features of the COPD population
are presented in Table 1. Three-quarters (75.6%) of the
study population were male (from 49.5% male in Lebanon
to 96.2% in Algeria). The level of smoking was similar across
all countries since smoking 10 pack·years was part of the
epidemiological deﬁnition of COPD. A total of 696 subjects
(50.1%) considered themselves to be in good, very good
or excellent health, 688 (49.4%) reported at least one
comorbidity and 643 (64.5%) were overweight.
Diagnosis and duration of symptoms
Data relating to the diagnosis and duration of COPD
symptoms were collected and summarised in Table 2. Only
one-third (31.8%) of the population claimed to have received
a diagnosis of COPD from a physician. The rate of diagnosis
was particularly low in Algeria (1.0%) and Morocco (3.9%)
and was highest in Pakistan (83.3%). The mean age at
the ﬁrst onset of persistent coughing with phlegm was
S36 M. Idrees et al.
Ta
bl
e
1
Ch
ar
ac
te
ri
st
ic
s
of
su
bj
ec
ts
w
it
h
CO
PD
in
ea
ch
of
th
e
pa
rt
ic
ip
at
in
g
M
EN
A
co
un
tr
ie
s.
N
A:
da
ta
no
t
av
ai
la
bl
e.
Al
ge
ri
a
Eg
yp
t
Jo
rd
an
Le
ba
no
n
M
or
oc
co
Pa
ki
st
an
Sa
ud
iA
ra
bi
a
Sy
ri
a
Tu
ni
si
a
Tu
rk
ey
U
AE
To
ta
l
A
ge
gr
ou
p
10
5
17
2
14
0
11
1
77
30
21
6
11
4
53
34
7
27
1,
39
2
40
49
ye
ar
s
26
(2
4.
8%
)
68
(3
9.
5%
)
64
(4
5.
7%
)
34
(3
0.
6%
)
36
(4
6.
8%
)
8
(2
6.
7%
)
11
6
(5
3.
7%
)
48
(4
2.
1%
)
19
(3
5.
8%
)
10
1
(2
9.
1%
)
15
(5
5.
6%
)
53
5
(3
8.
4%
)
50
59
ye
ar
s
42
(4
0.
0%
)
61
(3
5.
5%
)
36
(2
5.
7%
)
38
(3
4.
2%
)
22
(2
8.
6%
)
10
(3
3.
3%
)
68
(3
1.
5%
)
44
(3
8.
6%
)
17
(3
2.
1%
)
13
9
(4
0.
1%
)
10
(3
7.
0%
)
48
7
(3
5.
0%
)

60
ye
ar
s
37
(3
5.
2%
)
43
(2
5.
0%
)
40
(2
8.
6%
)
39
(3
5.
1%
)
19
(2
4.
7%
)
12
(4
0.
0%
)
32
(1
4.
8%
)
22
(1
9.
3%
)
17
(3
2.
1%
)
10
7
(3
0.
8%
)
2
(7
.4
%)
37
0
(2
6.
6%
)
G
en
de
r
10
5
17
2
14
0
11
1
77
30
21
6
11
4
53
34
7
27
1,
39
2
M
al
e
10
1
(9
6.
2%
)
14
9
(8
6.
6%
)
11
7
(8
3.
6%
)
55
(4
9.
5%
)
72
(9
3.
5%
)
25
(8
3.
3%
)
18
5
(8
5.
6%
)
81
(7
1.
1%
)
50
(9
4.
3%
)
19
2
(5
5.
3%
)
25
(9
2.
6%
)
1,
05
2
(7
5.
6%
)
Fe
m
al
e
4
(3
.8
%)
23
(1
3.
4%
)
23
(1
6.
4%
)
56
(5
0.
5%
)
5
(6
.5
%)
5
(1
6.
7%
)
31
(1
4.
4%
)
33
(2
8.
9%
)
3
(5
.7
%)
15
5
(4
4.
7%
)
2
(7
.4
%)
34
0
(2
4.
4%
)
Sm
ok
in
g
ex
po
su
re
10
5
17
2
14
0
11
1
77
30
21
6
11
4
53
34
7
27
1,
39
2
Ci
ga
re
tt
e
sm
ok
er
s
10
5
16
5
13
5
11
1
77
30
20
5
11
3
53
33
4
27
1,
35
5
<
10
pa
ck
·y
rs
0
(0
.0
%)
0
(0
.0
%)
0
(0
.0
%)
1
(0
.9
%)
0
(0
.0
%)
0
(0
.0
%)
0
(0
.0
%)
0
(0
.0
%)
0
(0
.0
%)
2
(0
.6
%)
0
(0
.0
%)
3
(0
.2
%)

10
pa
ck
·y
rs
10
5
(1
00
.0
%)
16
5
(1
00
.0
%)
13
5
(1
00
.0
%)
11
0
(9
9.
1%
)
77
(1
00
.0
%)
30
(1
00
.0
%)
20
5
(1
00
.0
%)
11
3
(1
00
.0
%)
53
(1
00
.0
%)
33
2
(9
9.
4%
)
27
(1
00
.0
%)
1,
35
2
(9
9.
8%
)
W
at
er
pi
pe
us
er
s
1
18
5
9
N
A
1
57
4
N
A
3
4
10
2
<
5
yr
s
1
(1
00
.0
%)
7
(3
8.
9%
)
3
(6
0.
0%
)
3
(3
3.
3%
)
N
A
0
(0
.0
%)
22
(3
8.
6%
)
1
(2
5.
0%
)
N
A
3
(1
00
.0
%)
1
(2
5.
0%
)
41
(4
0.
2%
)

5
yr
s
0
(0
.0
%)
11
(6
1.
1%
)
2
(4
0.
0%
)
6
(6
6.
7%
)
N
A
1
(1
00
.0
%)
35
(6
1.
4%
)
3
(7
5.
0%
)
N
A
0
(0
.0
%)
3
(7
5.
0%
)
61
(5
9.
8%
)
Bo
dy
M
as
s
In
de
x
(B
M
I)
75
10
2
12
2
81
75
29
14
3
80
50
22
3
16
99
6
U
nd
er
w
ei
gh
t:
<
18
.5
3
(4
.0
%)
3
(2
.9
%)
3
(2
.5
%)
2
(2
.5
%)
1
(1
.3
%)
4
(1
3.
8%
)
1
(0
.7
%)
3
(6
.0
%)
4
(1
.8
%)
24
(2
.4
%)
N
or
m
al
w
ei
gh
t:
18
.5
<
25
.0
35
(4
6.
7%
)
32
(3
1.
4%
)
35
(2
8.
7%
)
27
(3
3.
3%
)
42
(5
6.
0%
)
15
(5
1.
7%
)
34
(2
3.
8%
)
30
(3
7.
5%
)
18
(3
6.
0%
)
59
(2
6.
5%
)
2
(1
2.
5%
)
32
9
(3
3.
0%
)
O
ve
rw
ei
gh
t:
25
.0
<
30
.0
23
(3
0.
7%
)
31
(3
0.
4%
)
40
(3
2.
8%
)
29
(3
5.
8%
)
22
(2
9.
3%
)
5
(1
7.
2%
)
55
(3
8.
5%
)
26
(3
2.
5%
)
18
(3
6.
0%
)
93
(4
1.
7%
)
6
(3
7.
5%
)
34
8
(3
4.
9%
)
O
be
se
:

30
14
(1
8.
7%
)
36
(3
5.
3%
)
44
(3
6.
1%
)
23
(2
8.
4%
)
10
(1
3.
3%
)
5
(1
7.
2%
)
53
(3
7.
1%
)
24
(3
0.
0%
)
11
(2
2.
0%
)
67
(3
0.
0%
)
8
(5
0.
0%
)
29
5
(2
9.
6%
)
G
en
er
al
he
al
th
st
at
us
10
2
17
2
14
0
11
1
77
30
21
6
11
4
52
34
7
27
1,
38
8
Ex
ce
lle
nt
0
(0
.0
%)
9
(5
.2
%)
11
(7
.9
%)
10
(9
.0
%)
1
(1
.3
%)
2
(6
.7
%)
29
(1
3.
4%
)
8
(7
.0
%)
1
(1
.9
%)
2
(0
.6
%)
5
(1
8.
5%
)
78
(5
.6
%)
Ve
ry
go
od
to
go
od
50
(4
9.
0%
)
66
(3
8.
4%
)
81
(5
7.
9%
)
44
(3
9.
6%
)
42
(5
4.
5%
)
9
(3
0.
0%
)
13
7
(6
3.
4%
)
47
(4
1.
2%
)
34
(6
5.
4%
)
10
0
(2
8.
8%
)
8
(2
9.
6%
)
61
8
(4
4.
5%
)
Fa
ir
44
(4
3.
1%
)
76
(4
4.
2%
)
36
(2
5.
7%
)
40
(3
6.
0%
)
26
(3
3.
8%
)
10
(3
3.
3%
)
31
(1
4.
4%
)
42
(3
6.
8%
)
14
(2
6.
9%
)
40
(1
1.
5%
)
12
(4
4.
4%
)
37
1
(2
6.
7%
)
Po
or
to
ve
ry
po
or
8
(7
.8
%)
21
(1
2.
2%
)
12
(8
.6
%)
17
(1
5.
3%
)
8
(1
0.
4%
)
9
(3
0.
0%
)
19
(8
.8
%)
17
(1
4.
9%
)
3
(5
.8
%)
20
5
(5
9.
1%
)
2
(7
.4
%)
32
1
(2
3.
1%
)
Co
m
or
bi
di
ti
es
10
5
17
2
14
0
11
1
77
30
21
6
11
4
53
34
7
27
1,
39
2
Ye
s
45
(4
2.
9%
)
99
(5
7.
6%
)
90
(6
4.
3%
)
70
(6
3.
1%
)
43
(5
5.
8%
)
8
(2
6.
7%
)
13
2
(6
1.
1%
)
59
(5
1.
8%
)
30
(5
6.
6%
)
98
(2
8.
2%
)
14
(5
1.
9%
)
68
8
(4
9.
4%
)
BREATHE study: management of COPD in the MENA region S37
Table 2
Diagnosis and duration of symptoms by country
Algeria Egypt Jordan Lebanon Morocco Pakistan Saudi
Arabia
Syria Tunisia Turkey UAE Total
N = 105 N= 172 N = 140 N = 111 N= 77 N= 30 N= 216 N= 114 N= 53 N= 347 N= 27 N= 1,392
Age at ﬁrst
PCP
38.9
±13.3
42.9
±10.4
42.8
±12.5
42.7
±11.6
44.2
±8.6
49.3
±10.9
38.8
±10.1
42.6
±8.5
48.9
±11.7
43.7
±11.6
39.6
±7.6
42.5
±11.2
Age at ﬁrst
dyspnea
48.8
±11.0
45.3
±10.4
43.2
±11.8
47.9
±12.6
43.8
±8.5
47.1
±12.84
40.9
±10.2
42.7
±9.7
45.8
±12.9
44.9
±10.9
40.1
±10.9
44.5
±11.1
Known COPD
diagnosis
1
(1.0%)
51
(29.7%)
24
(17.1%)
32
(28.8%)
3
(3.9%)
25
(83.3%)
85
(39.4%)
29
(25.4%)
9
(17.0%)
175
(50.6%)
8
(29.6%)
442
(31.8%)
PCP, persistent coughing with phlegm; NA, data not available.
n=1
n=44
n=59 n=47
n=31
n=4
n=67 n=34
n=17 n=116
n=15
n=435
n=1
n=15
n=34
n=34
n=17
n=3
n=48
n=18
n=13
n=92
n=12
n=287
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(n=172)
Jordan
(n=140)
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(n=30)
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(n=216)
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(114)
Tunisia
(n=53)
Turkey
(n=347)
UAE
(n=27)
Total
(n=1 392),
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Figure 2. Use of spirometry in North Africa, the Middle East and Pakistan.
42.5±11.2 years and the mean age at the ﬁrst onset of
dyspnoea was 44.5±11.1 years.
Spirometry results
Of the 1,392 subjects interviewed, only one-third (n = 435;
31.3%) had previously had their lung function tested
by spirometry (from 1.0% in Algeria to 55.6% in UAE)
(Fig. 2). Two-thirds of these subjects (287/433; 66.3%) had
undergone a spirometry test at least once in the past year.
Treatment of COPD
The rate of treatment of COPD was low. For all countries to-
gether, 50.5% [95%CI: 47.9 53.1%] of subjects had received
treatment for their respiratory symptoms (from 37.0%
[95%CI: 18.8 55.3%] in UAE to 83.3% [95%CI: 70.0 96.7%]
in Pakistan) (Table 3).
Overall, 54.2% of subjects (218/402) treated for respira-
tory symptoms reported use of a speciﬁc treatment, most
frequently bronchodilators (b-agonists or anticholinergics),
used by 203 subjects (50.5%) and, in particular, long-acting
b-agonists (Table 3). The use of both bronchodilators and in-
haled corticosteroids (ICS) was reported by 13.2% of treated
subjects. Fixed combinations of long-acting bronchodilators
and ICS were reported by only 22 subjects (5.5%) and were
essentially limited to three countries (Lebanon, Morocco and
Turkey) (Table 3). The use of other (non-speciﬁc) treatments
was reported by 45.8% of subjects, essentially antibacterial
treatments (17.9%).
Home oxygen therapy was used infrequently in the
different countries. Overall, only 2.3% [95%CI: 1.5 3.1%]
had used home oxygen therapy every or most days in the
past year (from 0% [95%CI: 0.0 0.0%] in Tunisia and Jordan
to 7.1% [95%CI: −2.1 16.4%] in Pakistan (Table 3).
Physician consultations and hospitalisations
COPD was an important medical problem in the lives of
participants in the study, and around two-thirds (61.2%
[95%CI: 58.6 63.8%]) had consulted a physician about their
respiratory condition at least one time in the previous
S38 M. Idrees et al.
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12 months (from 48.8% [95%CI: 41.4 56.3%] in Egypt to
90.0% [95%CI: 79.3 100.0%] in Pakistan), with a mean
number of consultations of 3.4±3.6. Furthermore, nearly
half (45.8%) of the COPD population consulted a specialist
chest/respiratory physician (from 12.3% in Algeria to
65.3% in Lebanon) (Table 4).
Overall, 284 (20.4%) subjects had been hospitalised
overnight or longer as a result of their COPD (from 10.5%
[95%CI: 4.6 16.3%] in Algeria to 40.7% [95%CI: 22.2 59.3%]
in UAE), with a mean of 2.3±3.7 hospitalisations per year and
a mean of 5.8±8.7 nights stay in hospital (Table 4). Nearly
one-ﬁfth of subjects (249; (17.9% [95%CI: 15.9 19.9%]) had
presented to an emergency room because of their COPD
symptoms (from 3.9% [95%CI: −0.4 8.9%] in Morocco and
Tunisia to 29.6% [95%CI: 23.5 35.7%] in Saudi Arabia), with
a mean of 3.5±5.1 visits to an emergency room for the COPD
population as a whole (Table 4).
Smoking cessation
Overall, one third of subjects (33.9%) had tried to give up
smoking (from 13.3% in Algeria to 51.1% in Jordan) and one-
third (35.7%; range: 11.8% in Morocco to 61.9% in Lebanon)
of the COPD subjects had a family member who smoked.
There was a large range in the percentage of subjects in
each country who had received advice from their physician
in the previous 12 months to give up smoking (68.6% overall;
from 25% in Tunisia to 85.7% in UAE) (Table 5).
Classiﬁcation of COPD subjects according to
CAT score and exacerbation history
A total of 1,014 of the 1,392 COPD subjects (72.8%) were
classiﬁable according to their CAT score and exacerbation
history. Of these subjects, 147 (14.5%) were in GOLD
group A, 233 (23.0%) in Group B, 86 (8.5%) in Group C and
548 (54.0%) in Group D (Table 6).
Overall, there was no signiﬁcant difference in the gender
(p = 0.462) of subjects between the four GOLD groups
whereas the age distribution was signiﬁcantly different,
with the age group of 40 49 years being more highly
represented in the higher-level GOLD groups. Subjects in
the higher-level GOLD groups more frequently reported
having received a diagnosis of COPD (p < 0.0001) and being
regular smokers (p = 0.002). For the subgroup of patients
who underwent spirometry for the purposes of the study, a
negative association (p < 0.0001) between %FEV1 values and
GOLD group level was observed.
The distribution of the different variables pertaining
to disease management according to their GOLD 2011
classiﬁcation is presented in Table 7. Overall, the frequency
of reported use was higher in subjects with CAT scores 10
than in those with scores <10, and greater in those with
exacerbations than in those without. A signiﬁcant difference
(p < 0.001) between GOLD groups was observed for all these
variables, except for oxygen therapy (p = 0.162) and speciﬁc
treatment (p = 0.087).
Discussion
The BREATHE study is an international study which assessed
the management of COPD in a representative sample of
the general population of eleven countries of the MENA
region using the same standardised methodology. The
present analysis was performed in 1,392 subjects fulﬁlling
the epidemiological deﬁnition of COPD, focussing on the
diagnosis, treatment and principal healthcare resources
used in each participating country. These variables were also
described according to the 2011 GOLD classiﬁcation based
on CAT scores and the risk of exacerbations.
Among the 1,392 subjects in this study who fulﬁlled the
epidemiological deﬁnition of COPD, only 31.8% reported
having received a diagnosis of COPD from a physician.
This ﬁgure was highest in Pakistan (83.3%) and lowest in
Algeria (1.0%) and Morocco (3.9%). This may be because
there is no term for COPD which has entered the vernacular
language in Arabic or the other mother tongues of the region
whereas, in Pakistan, English remains an important vehicle
for talking about medicine. For this reason, physicians,
as well as patients, in Arabic-speaking countries may use
different words or periphrases to identify their illness,
such as ‘smoker’s cough’. In addition, reported diagnosis
rates may also reﬂect access to care, and diagnosis
from a physician. Respondents from Algeria and Morocco
also reported low rates of lung function monitoring and
use of respiratory treatments, suggesting that barriers to
access to care may be important in these countries. To
our knowledge, there are only very few published data
on the rate of diagnosis of COPD in the MENA region,
thus complicating comparison of our results with previous
studies. In one previous study reported from Lebanon
in 2010, 20.2% of interviewees with symptoms of COPD
(n = 214) had previously been diagnosed with COPD.23 This
rate is close to that observed in the BREATHE study for
Lebanon (28.8%).
The BREATHE study indicated that only twenty percent
of subjects had performed spirometry in the previous year
and only thirty percent had ever had their lungs tested.
These proportions are lower than those reported in the
Confronting COPD study6,7 and suggest that respiratory
complaints are not generally being evaluated in an optimal
way in countries in the MENA region.
The frequency of use of healthcare resources for COPD
in the past year in the BREATHE study was also compared to
the corresponding data from the Confronting COPD study,6,7
which used a similar methodology and questionnaire to the
BREATHE study (Table 8).
In the BREATHE study, two-thirds of subjects (61.2%)
had consulted a physician for their respiratory condition in
the previous 12 months. Although this rate is lower than
the 82.2% reported in the Confronting COPD study,6,7 it
still indicates that subjects considered their respiratory
symptoms to be an important medical problem, since
nearly two thirds had consulted at least once in the
previous year and the mean number of consultations in the
previous year was 3.4, representing one visit every three
to four months. The difference in the rates of consultation
between the BREATHE study and those of the Confronting
S40 M. Idrees et al.
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COPD study6,7 might be explained by differences related
to access to healthcare but also by differences in social
beliefs and attitudes to disease. Indeed, in the MENA
region, many people, particularly those who smoke, may
consider that having respiratory symptoms at their age is
‘normal’. In this respect, it is noteworthy that even though
these subjects were frequently consulting a physician about
their respiratory symptoms, at some ﬁnancial cost in most
countries, around one half claimed that they considered
themselves to be in excellent, very good or good health.
Overall, nearly one-half of subjects (45.8%) had con-
sulted a specialist respiratory/chest physician, while 20.5%
consulted their GP. In Algeria however, only 10.7% of
subjects had visited a specialist respiratory physician,
possibly because community clinics represent the reference
care provider for most of the population. Thus, in Algeria
more subjects visited their GP (in the community clinic
or private ofﬁce) or ‘other’ physicians (44.6% each) for
advice. Conversely, in Lebanon, which is a more densely
populated country with many accessible hospitals and a
well-developed private sector, 64.2% of subjects visited a
specialist respiratory physician. These results contrast with
those of the Confronting COPD study where nearly two-
thirds of subjects (62.4%) in Europe and North America are
managed by their GP.6,7 It is interesting in the BREATHE study
that although two-thirds of subjects had seen a physician
about their respiratory condition, only one-third claimed
that they had been given a diagnosis of COPD by their
physician. These results may reﬂect low awareness about
COPD, leading to problems of differential diagnosis. For
example, a recent study24 in Spain reported that physicians
have some difﬁculties in differentiating COPD and asthma.
The results of the BREATHE study might also reﬂect low
general awareness of physicians about the burden and
consequences of COPD, which precludes a proactive and
vigorous approach to diagnosis and treatment. This underlies
the necessity to improve education about this disease in
order to increase awareness and facilitate a timely diagnosis
and initiation of an appropriate treatment.
Approximately one-ﬁfth of subjects (21.0%) overall had
been hospitalised because of their COPD symptoms. This
was roughly similar in all countries except for Algeria and
Tunisia, where only 11.0% and 11.5% of subjects respectively
had been hospitalised overnight or longer, and the UAE,
where 42.4% had been hospitalised. Similarly, 18.5% of
subjects overall had visited an emergency room because
of their respiratory condition. This latter ﬁgure ranged
from 3.8% and 3.9% respectively in Tunisia and Morocco
to 30.5% in Saudi Arabia. The overall ﬁgures of 21.0% for
hospitalisations and 18.5% for emergency visits are higher
than the respective ﬁgures in the Confronting COPD study
(12.8% and 13.8%, respectively). This could be due to the
fact that a lower proportion of subjects in the BREATHE study
were diagnosed and appropriately treated.
Only 50.5% of subjects were currently taking medication
for their respiratory symptoms in the BREATHE study.
Medication use ranged from 37.0% in the UAE to 83.3% in
Pakistan and this difference could be at least partly
responsible for the higher percentage of hospitalisations for
COPD in the UAE (42.3%) compared to Pakistan (33.3%).
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In addition, of the patients who were treated, only half
were taking a speciﬁc treatment recommended in the GOLD
guidelines (bronchodilators or inhaled corticosteroids or
both). Indeed, use of both long-acting bronchodilators and
ICS (either in ﬁxed combinations or free associations) was
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Table 6
Classiﬁcation of COPD subjects (n = 1,014) according to symptoms (CAT score) and exacerbation history (adapted from the
2011 GOLD report5). The presence of exacerbations was assessed over a period of six months.
Variables Exacerbation
NO
CAT score <10 CAT score 10
YES
CAT score <10 CAT score 10
Group A (N = 147) Group B (N = 233) Group C (N = 86) Group D (N = 548)
Gender
Male 117 (79.6%) 180 (77.3%) 69 (80.2%) 409 (74.6%)
Female 30 (20.4%) 53 (22.7%) 17 (19.8%) 139 (25.4%)
Age
40 49 years 56 (38.1%) 91 (39.1%) 24 (27.9) 174 (40.9%)
50 59 years 61 (41.5%) 79 (33.9%) 32 (37.2%) 165 (30.1%)
60 years 30 (20.4%) 63 (27.0%) 30 (34.9%) 144 (26.3%)
Regular smokers 75 (52.4%) 145 (62.8%) 51 (59.3%) 378 (69.0%)
COPD diagnosis 20 (13.6%) 50 (21.5%) 20 (23.3%) 204 (37.2%)
%FEV1 (mean ± SD) 86.5±33.3 80.9±19.9 86.4±18.9 78.2±32.0
Comorbidities 66 (44.9%) 115 (49.4%) 38 (44.2%) 298 (54.4%)
Cardiovascular comorbidity 44 (29.9%) 78 (33.5%) 30 (34.9%) 174 (31.8%)
Table 7
Disease management according to GOLD severity grade (adapted from the 2011 GOLD report5). The presence of exacerbations
was assessed over a period of six months
Variables Exacerbation
NO
CAT score <10 CAT score 10
YES
CAT score <10 CAT score 10
Group A (N = 147) Group B (N = 233) Group C (N = 86) Group D (N = 548)
Any medication 62 (42.2%) 117 (50.2%) 47 (54.7%) 396 (72.3%)
Respiratory treatment 33 (22.4%) 47 (20.2%) 13 (15.1%) 194 (35.4%)
Speciﬁc respiratory treatment 20 (13.6%) 29 (12.4%) 8 (9.3%) 134 (24.5%)
Bronchodilatators (BD) 19 (12.9%) 27 (11.6%) 7 (8.1%) 127 (23.2%)
ICS 5 (3.4%) 8 (3.4%) 4 (4.7%) 42 (7.7%)
Combination BD+ICS 4 (2.7%) 6 (2.6%) 3 (3.5%) 35 (6.4%)
Oxygen therapy 1 (0.7%) 4 (1.7%) 2 (2.3%) 20 (3.6%)
Physician consultation 72 (49.0%) 114 (48.9%) 56 (65.1%) 428 (78.1%)
Hospitalisations 15 (10.2%) 27 (11.6%) 11 (12.8%) 151 (27.6%)
Emergency visits 10 (6.8%) 24 (10.3%) 5 (5.8%) 132 (24.1%)
reported by less than ﬁve percent of subjects in the COPD
population. Barriers to access to medication may contribute
to the limited use of recommended speciﬁc respiratory
treatments in certain countries and it is likely that these
medications are only being prescribed to a minority of
patients. Broader dissemination of the GOLD treatment
recommendation, particularly in community medicine, or
alternatively local guidelines targeted to this sector, may
be useful in improving this situation.
Oxygen therapy is currently one of the main non-
pharmacological treatments for subjects with Stage IV
COPD (very severe).1 Oxygen use was highest in Pakistan
and lowest in Turkey. In the most severe subjects with a
CAT score of 10 and a history of exacerbations (Group D),
10.1% [95%CI: 7.3 13.0%] of subjects received oxygen
therapy. The use of oxygen therapy was similar in the other
three groups (4.9%, 2.4% and 5.8% for groups C, A and B,
respectively).
Stopping smoking is the single most important interven-
tion in COPD in order to prevent, delay or slow down airﬂow
limitation, with subsequent beneﬁts on both symptom
progression and survival.1 However, two-thirds of subjects
(64.5%; ranging from 48.5% in Algeria to 82.4% in UAE)
involved in the BREATHE study were current smokers at
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Table 8
Comparison of the use of health care resources (% of subjects) in the past year in the MENA region and in the
Confronting COPD study6,7
MENA region (n = 1,392) North America and Europe6,7 (n = 3,265)
Consultation of a physician 61.2% 82.2%
Hospitalisations 20.4% 12.8%
Emergency care 17.9% 13.8%
Medical speciality consulted
GP 21.2% 62.4%
Specialist respiratory/chest physician 45.8% 19.6%
Other 33.0% 15.0%
Spirometry 31.3% 45.5%
Oxygenotherapy <10% NA
Currently taking medication 50.5% 61.1%
the time of the study, and two-thirds of these current
smokers had never tried to give up (66.1%; ranging from
48.9% in Jordan to 86.7% in Algeria). Around one-third
(31.4%) claimed that their physician had never advised them
to give up smoking. However, there was a wide variation in
the proportion of subjects in each country who had been
advised by their physician to give up smoking (25% in Tunisia
to 85.7% in UAE). Thus, physicians should be encouraged to
advise patients presenting with early symptoms of COPD to
give up smoking and to inform them about the availability
of counselling and other therapeutic aids to help them
do so. In most countries, management of addictions is a
neglected area of medical training, even though it has
important repercussions on health in general and, in the
case of smoking, on the risk of severe and life-threatening
respiratory diseases. A greater emphasis on the importance
of addiction in the curricula of medical schools would be
of beneﬁt to physicians when treating patients who wish or
need to give up smoking.
All COPD subjects involved in the study were classiﬁed
into one of the four severity groups based on CAT scores
and exacerbation risk that were proposed in the 2011 GOLD
guidelines. On this basis, the rates of healthcare use be-
tween severity groups could be compared. It should be noted
that the 2011 guidelines represent a purely symptomatic
classiﬁcation, since exacerbation history can be used as an
alternative to spirometry. The severity groups thus deter-
mined may thus not match exactly previous GOLD classiﬁca-
tions based on lung function testing. Our classiﬁcation does
not fully respect the GOLD recommendations which classify
risk into 2 and <2 exacerbations in the previous year. Since
the number of exacerbations was not available from the
study questionnaire, which was designed and implemented
before the GOLD guidelines were published, risk was classi-
ﬁed into 1 or no exacerbations in the previous six months.
However, given the different time base, the presence of 1
exacerbations over six months can be considered equivalent
to the2 exacerbations over one year proposed in the GOLD
guideline. The age group of 40 49 years seems to be more
affected by COPD than the other age groups in terms of
worsening of their health status, being over-represented in
the higher GOLD grades. With respect to healthcare resource
use, strong associations were observed between the extent
of use and GOLD severity grade.
One of the potential limitations of the BREATHE is that the
methodology of the study was oriented to the assessment
of the management of COPD from the subject’s perspective
only. Consequently, the study collected data based on
subject self-reported diagnosis and treatment, without any
possibility for physician ascertainment. This may introduce
some inaccuracy, particularly if subjects misunderstood the
diagnosis or did not know the exact type of treatment
used. In addition, given the large number of questions
(77 questions), it was difﬁcult for some responders to
complete the interview in a single session. Consequently,
the exhaustivity and accuracy of data collection may have
diminished towards the end of the questionnaire.
In conclusion, the BREATHE study indicates that COPD in
the MENA region is under-diagnosed, insufﬁciently evaluated
and inadequately treated. On the other hand, COPD
symptoms were responsible for considerable healthcare
consumption, with high levels of physician consultation
and hospitalisation. These ﬁndings underlie the lack of
information about the management of COPD and the need
for more physician and patient awareness about this chronic
disease.
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